drugset / Trial / NCT00370253

Noradrenalin vs Terlipressin in Hepatorenal Syndrome

NCT00370253

Phase 3 Completed 20 enrolled University of Turin, Italy
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether noradrenalin is as effective and safe as terlipressin in the treatment of hepatorenal syndrome

Timeline

Start
2006-09
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Noradrenalin Unknown 0.1 ug/kg
Comparator Terlipressin Peptide 1 mg

Indications